Green Thumb Industries (GTBIF) Non-Current Assets (2019 - 2026)
Green Thumb Industries' (GTBIF) quarterly Non-Current Assets came in at $2.2 billion in Q1 2026, up 1.58% YoY from $2.1 billion in Q1 2025, and down 2.49% on a QoQ basis from $2.2 billion in Q4 2025.
Green Thumb Industries (GTBIF) Non-Current Assets (2019 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 8 years of Non-Current Assets data on file, last reported at $2.2 billion in Q1 2026.
- Quarterly Non-Current Assets rose 1.58% year-over-year to $2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 billion (up 1.86% YoY) and the FY2025 annual result came in at $2.2 billion, up 3.74% from the prior year.
- Non-Current Assets declined to $2.2 billion in Q1 2026, from $2.2 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $2.2 billion in Q4 2025 to a low of $1.7 million in Q1 2022.
- A 5-year average of $1.8 billion and a median of $2.1 billion in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets sank 51.12% — and 2023, when it surged 122421.86%.
- Tracing GTBIF's Non-Current Assets over 5 years: stood at $1.9 million in 2022, then jumped by 112382.71% to $2.1 billion in 2023, then retreated by 0.66% to $2.1 billion in 2024, then grew by 3.74% to $2.2 billion in 2025, then decreased by 2.49% to $2.2 billion in 2026.
- The last three Non-Current Assets figures came in at $2.2 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Green Thumb Industries | 1.65 Bn | 1.37 Bn | 137.87 Mn | 2.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.19 Bn |
| Mar 31, 2026 | 2.16 Bn |
| Dec 31, 2025 | 2.21 Bn |
| Sep 30, 2025 | 2.16 Bn |
| Jun 30, 2025 | 2.14 Bn |
| Mar 31, 2025 | 2.12 Bn |
| Dec 31, 2024 | 2.13 Bn |
| Sep 30, 2024 | 2.12 Bn |
| Jun 30, 2024 | 2.14 Bn |
| Mar 31, 2024 | 2.14 Bn |
| Dec 31, 2023 | 2.15 Bn |
| Sep 30, 2023 | 2.18 Bn |
| Jun 30, 2023 | 2.17 Bn |
| Mar 31, 2023 | 2.14 Bn |
| Dec 31, 2022 | 1.91 Mn |
| Sep 30, 2022 | 1.97 Mn |
| Jun 30, 2022 | 2.12 Bn |
| Mar 31, 2022 | 1.74 Mn |
| Dec 31, 2021 | 3.29 Mn |
| Sep 30, 2021 | 1.82 Mn |